Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin

Background & Aims: Recently, we reported that liver Label Retaining Cancer Cells (LRCC) can initiate tumors with only 10 cells and are relatively resistant to the targeted drug Sorafenib, a standard of practice in advanced hepatocellular carcinoma (HCC). LRCC are the only cancer stem cells (CSC)...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Cancer
Autori principali: Xin, Hong-Wu, Ambe, Chenwi M., Miller, Tyler C., Chen, Jin-Qiu, Wiegand, Gordon W., Anderson, Andrew J., Ray, Satyajit, Mullinax, John E., Hari, Danielle M., Koizumi, Tomotake, Godbout, Jessica D., Goldsmith, Paul K., Stojadinovic, Alexander, Rudloff, Udo, Thorgeirsson, Snorri S., Avital, Itzhak
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ivyspring International Publisher 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4911882/
https://ncbi.nlm.nih.gov/pubmed/27326258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.10047
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi